Personalized GLP-1 Therapy Based on Your Genetic Profile Not everyone responds identically to the same GLP-1 medication
What the clinical evidence on Wegovy shows Wegovy (semaglutide 2.4 mg, given weekly by subcutaneous injection) has been FDA-approved for chronic weight management since June 2021
The cost of Wegovy depends on many factors
However, the morning routine restrictions may not suit everyone
Book online or call (915) 266-3174
3 , 10 , 11 However, further investigation is needed to delineate the specific efficacy and safety profiles of GLP-1 RAs in patient populations with comorbid DM, chronic kidney disease (CKD), obesity, or heart failure (HF)